血清 HSP70 和血管内皮生长因子水平是胰腺癌患者化疗敏感性和预后的有效预测因素。

IF 1.7 4区医学 Q3 GASTROENTEROLOGY & HEPATOLOGY

Pancreas Pub Date : 2024-10-01 Epub Date: 2024-03-26 DOI:10.1097/MPA.0000000000002358

Liumei Xiong, Danming Li, Gui Xiao, Sipin Tan, Jianbo Wen, Guiliang Wang

{"title":"血清 HSP70 和血管内皮生长因子水平是胰腺癌患者化疗敏感性和预后的有效预测因素。","authors":"Liumei Xiong, Danming Li, Gui Xiao, Sipin Tan, Jianbo Wen, Guiliang Wang","doi":"10.1097/MPA.0000000000002358","DOIUrl":null,"url":null,"abstract":"Aim: The study is to evaluate serum HSP70 and VEGF for predicting the chemoradiosensitivity of the pancreatic cancer patients.Materials and methods: 255 pancreatic cancer patients and 60 healthy subjects were measured for serum HSP70 and VEGF using ELISA for the pretreatment, during treatment, and postchemoradiotherapy timepoints.Results: The serum HSP70 and VEGF were found to be elevated in pancreatic cancer patients as compared to healthy subjects. After chemoradiotherapy treatment, 179 patients showed effective clinical response while 76 patients showed ineffective clinical response. Serum HSP70 and VEGF were higher during chemoradiotherapy, and lower posttreatment in the effective group. However, serum HSP70 and VEGF were higher during and after treatment in the ineffective group. At any given timepoint, serum HSP70 and VEGF were higher in the ineffective group compared with the effective group. The overall survival and progression-free survival trends were as follows: HSP70 High /VEGF High < HSP70 High /VEGF Low or HSP70 Low /VEGF High < HSP70 Low /VEGF Low . Serum HSP70 and VEGF were individually effective, and their combination was even more effective in predicting the chemoradiosensitivity of pancreatic cancer patients. HSP70 and VEGF were independent risk factors for overall survival and progression-free survival of pancreatic cancer patients.Conclusions: Low levels of serum HSP70 and VEGF were associated with improved radiosensitivity and better prognosis of pancreatic cancer patients.","PeriodicalId":19733,"journal":{"name":"Pancreas","volume":" ","pages":"e713-e722"},"PeriodicalIF":1.7000,"publicationDate":"2024-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Serum HSP70 and VEGF Levels Are Effective Predictive Factors of Chemoradiosensitivity and Prognosis of Pancreatic Cancer Patients.\",\"authors\":\"Liumei Xiong, Danming Li, Gui Xiao, Sipin Tan, Jianbo Wen, Guiliang Wang\",\"doi\":\"10.1097/MPA.0000000000002358\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Aim: The study is to evaluate serum HSP70 and VEGF for predicting the chemoradiosensitivity of the pancreatic cancer patients.Materials and methods: 255 pancreatic cancer patients and 60 healthy subjects were measured for serum HSP70 and VEGF using ELISA for the pretreatment, during treatment, and postchemoradiotherapy timepoints.Results: The serum HSP70 and VEGF were found to be elevated in pancreatic cancer patients as compared to healthy subjects. After chemoradiotherapy treatment, 179 patients showed effective clinical response while 76 patients showed ineffective clinical response. Serum HSP70 and VEGF were higher during chemoradiotherapy, and lower posttreatment in the effective group. However, serum HSP70 and VEGF were higher during and after treatment in the ineffective group. At any given timepoint, serum HSP70 and VEGF were higher in the ineffective group compared with the effective group. The overall survival and progression-free survival trends were as follows: HSP70 High /VEGF High < HSP70 High /VEGF Low or HSP70 Low /VEGF High < HSP70 Low /VEGF Low . Serum HSP70 and VEGF were individually effective, and their combination was even more effective in predicting the chemoradiosensitivity of pancreatic cancer patients. HSP70 and VEGF were independent risk factors for overall survival and progression-free survival of pancreatic cancer patients.Conclusions: Low levels of serum HSP70 and VEGF were associated with improved radiosensitivity and better prognosis of pancreatic cancer patients.\",\"PeriodicalId\":19733,\"journal\":{\"name\":\"Pancreas\",\"volume\":\" \",\"pages\":\"e713-e722\"},\"PeriodicalIF\":1.7000,\"publicationDate\":\"2024-10-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pancreas\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1097/MPA.0000000000002358\",\"RegionNum\":4,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"2024/3/26 0:00:00\",\"PubModel\":\"Epub\",\"JCR\":\"Q3\",\"JCRName\":\"GASTROENTEROLOGY & HEPATOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pancreas","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1097/MPA.0000000000002358","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/3/26 0:00:00","PubModel":"Epub","JCR":"Q3","JCRName":"GASTROENTEROLOGY & HEPATOLOGY","Score":null,"Total":0}

引用次数: 0

摘要

目的：评估血清HSP70和血管内皮生长因子水平对胰腺癌患者化疗敏感性的预测价值：方法：本研究共纳入 255 名胰腺癌患者和 60 名健康受试者。采用酶联免疫吸附试验（ELISA）测定治疗前、治疗中和化疗放疗后的血清 HSP70 和血管内皮生长因子水平。分析结果旨在评估血清 HSP70 和血管内皮生长因子水平预测胰腺癌患者化疗敏感性的潜力：结果：与健康人相比，胰腺癌患者血清中的 HSP70 和血管内皮生长因子水平均有所升高。化放疗后，179 例患者出现有效临床反应[完全反应（CR）+部分反应（PR）]，76 例患者出现无效临床反应[疾病稳定（SD）+疾病进展（PD）]。与治疗前水平相比，化放疗期间有效组患者血清中的 HSP70 和 VEGF 水平较高，治疗后较低。然而，无效组在治疗期间和治疗后的血清 HSP70 和 VEGF 水平较高。在任何给定的时间点，无效组血清中的HSP70和VEGF水平均高于有效组。总生存期（OS）和无进展生存期（PFS）的趋势分别为HSP70高/VEGF高本文章由计算机程序翻译，如有差异，请以英文原文为准。

查看原文本刊更多论文

Serum HSP70 and VEGF Levels Are Effective Predictive Factors of Chemoradiosensitivity and Prognosis of Pancreatic Cancer Patients.

Aim: The study is to evaluate serum HSP70 and VEGF for predicting the chemoradiosensitivity of the pancreatic cancer patients.

Materials and methods: 255 pancreatic cancer patients and 60 healthy subjects were measured for serum HSP70 and VEGF using ELISA for the pretreatment, during treatment, and postchemoradiotherapy timepoints.

Results: The serum HSP70 and VEGF were found to be elevated in pancreatic cancer patients as compared to healthy subjects. After chemoradiotherapy treatment, 179 patients showed effective clinical response while 76 patients showed ineffective clinical response. Serum HSP70 and VEGF were higher during chemoradiotherapy, and lower posttreatment in the effective group. However, serum HSP70 and VEGF were higher during and after treatment in the ineffective group. At any given timepoint, serum HSP70 and VEGF were higher in the ineffective group compared with the effective group. The overall survival and progression-free survival trends were as follows: HSP70 High /VEGF High < HSP70 High /VEGF Low or HSP70 Low /VEGF High < HSP70 Low /VEGF Low . Serum HSP70 and VEGF were individually effective, and their combination was even more effective in predicting the chemoradiosensitivity of pancreatic cancer patients. HSP70 and VEGF were independent risk factors for overall survival and progression-free survival of pancreatic cancer patients.

Conclusions: Low levels of serum HSP70 and VEGF were associated with improved radiosensitivity and better prognosis of pancreatic cancer patients.